Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

21. Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review

Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review | CADTH.ca Find the information you need Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Last updated: April 18, 2019 Project Number: RC1099-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are patients’ and clinicians’ expectations of gene expression profiling tests for breast cancer? How do patients and clinicians understand, communicate, and make decisions to undergo gene expression profiling testing for breast cancer? How do patients and clinicians understand, communicate and make decisions based on the results? How does the option, or not, of gene expression profile testing help to shape patients’, and clinicians’ experiences and perceptions

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration (...) Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 6, 2019 Project Number: RC1127-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of varying treatment sequences of androgen receptor targeted agents in patients with castrate-resistant prostate cancer? What is the comparative cost-effectiveness of varying treatment sequences of androgen

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

23. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness

Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Last updated: September 16, 2019 Project Number: RC1181-000 Product Line: Research (...) Type: Non-Pharma Mental Health Intervention Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of cognitive behavioural therapy for chronic non-cancer pain? Key Message There were five systematic reviews included in this report, four of which were Cochrane reviews. Four of the five included systematic reviews had one weakness in the AMSTAR critical domains. The clinical effectiveness of cognitive behavioural therapy was assessed in several

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

26. Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness (...) , Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: September 20, 2019 Project Number: RB1400-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of anal cancer screening in high risk populations? What is the diagnostic accuracy of Pap testing for anal cancer in high risk populations? What is the cost-effectiveness of anal cancer screening in high risk populations? What are the evidence-based

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

27. Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell Lung Cancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting

2019 CADTH - Pan Canadian Oncology Drug Review

28. Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details | CADTH.ca Find the information you need Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Project Number pCODR 10182 Brand Name Kadcyla Generic Name Trastuzumab Emtansine Tumour Type Breast Indication Early Breast Cancer (EBC) Funding Request For the adjuvant (...) treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy. Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Hoffmann-La Roche Limited Sponsor Hoffmann-La Roche Limited

2019 CADTH - Pan Canadian Oncology Drug Review

29. Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details

Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10195 Brand Name Kisqali Generic Name Ribociclib with Fulvestrant Tumour Type Breast Indication Advanced or Metastatic Breast (...) Cancer Funding Request In combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial therapy or following disease progression on endocrine therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type New Indication

2019 CADTH - Pan Canadian Oncology Drug Review

30. Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details

Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Project Number pCODR 10196 Brand Name TBD Generic Name Darolutamide Tumour Type Genitourinary Indication Non (...) -Metastatic Castration Resistant Prostate Cancer Funding Request In combination with androgen depravation therapy (ADT), for the treatment of patients with non-metastatic castration resistant prostate cancer who are at high risk of developing metastases (high risk defined as prostate-specific antigen doubling time ≤ 10 months) during continuous ADT, and have a good Eastern Cooperative Oncology Group (ECOG) performance status Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Bayer Inc

2019 CADTH - Pan Canadian Oncology Drug Review

31. Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details

Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details | CADTH.ca Find the information you need Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details Project Number pCODR 10173 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil (...) Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission No NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada

2019 CADTH - Pan Canadian Oncology Drug Review

32. Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details | CADTH.ca Find the information you need Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Project Number pCODR 10200 Brand Name Erleada Generic Name Apalutamide Tumour Type Genitourinary Indication Metastatic (...) Castration-Sensitive Prostate Cancer Funding Request For the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Janssen Inc. Sponsor Janssen Inc. Submission Date (Target Date) October 15, 2019 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ October 29, 2019 Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation

2019 CADTH - Pan Canadian Oncology Drug Review

33. Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness

Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness Last updated: September 27, 2019 Project Number: RC1193-000 Product Line: Research (...) Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of strength-based exercise for chronic non-cancer back pain? Key Message No evidence was found regarding the clinical effectiveness of strength-based exercise alone compared with pharmacological interventions for chronic non-cancer back pain in non-pregnant people. Files Rapid Response Summary with Critical Appraisal Published : September 27, 2019 Follow us: © 2019

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

34. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

35. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

36. Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC)

Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC) 1 Published 07 October 2019 1 SMC2195 enzalutamide 40mg soft capsules (Xtandi®) Astellas Pharma Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent process (...) enzalutamide (Xtandi ® ) is not recommended for use within NHSScotland. Indication under review: The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). In a phase III study in men with high-risk non-metastatic CRPC enzalutamide was superior to placebo for metastasis-free survival. High-risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2 nanograms/mL. Both groups received on-going androgen-deprivation therapy or had undergone

2019 Scottish Medicines Consortium

37. Pertuzumab (Perjeta) - HER2-positive early breast cancer

Pertuzumab (Perjeta) - HER2-positive early breast cancer 1 Published 07 October 2019 1 SMC2197 pertuzumab 420mg concentrate solution for infusion (Perjeta®) Roche Products Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent (...) process pertuzumab (Perjeta®) is not recommended for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease- free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature. The submitting

2019 Scottish Medicines Consortium

38. Mohs Surgery for Patients with Skin Cancer: A Review of Guidelines

Mohs Surgery for Patients with Skin Cancer: A Review of Guidelines Mohs Surgery for Patients with Skin Cancer: A Review of Guidelines | CADTH.ca Find the information you need Mohs Surgery for Patients with Skin Cancer: A Review of Guidelines Mohs Surgery for Patients with Skin Cancer: A Review of Guidelines Last updated: March 20, 2019 Project Number: RC1084-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the evidence-based guidelines regarding the use of Mohs surgery for the treatment of skin cancer? Key Message Nine evidence-based guidelines were identified; two guidelines issued recommendations on basal cell carcinoma, four on squamous cell carcinoma, two on melanoma, and one on Merkel cell carcinoma. Mohs micrographic surgery (MMS) is recommended as a first-line option for high-risk primary or recurrent basal cell carcinoma. For high-risk primary or recurrent squamous cell carcinoma, MMS may

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

39. Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness (...) and Guidelines Magnetic Resonance Imaging-Guided Radiotherapy Delivery Systems for Cancer Treatment: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Last updated: March 25, 2019 Project Number: RC1085-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of magnetic resonance imaging-guided radiotherapy delivery systems for the treatment of patients with cancer requiring

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

40. High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness (...) and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: February 14, 2019 Project Number: RC1070-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of high-dose-rate versus low-dose-rate brachytherapy for the treatment of prostate cancer? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review